

Supplemental Figure 1. Stratified Antibody Characterization at the time of de novo DSA detection and concomitant characteristics (n=113)

		Non-Adherence	MFI >10,000	DSA Class II	DSA Class I alone
n=4	<b>C1q(+)</b> <b>IgG3(+)</b> <b>IgG4(+)</b>	75%	100%	100%	0%
n=5	<b>C1q(-)</b> <b>IgG3(+)</b> <b>IgG4(+)</b>	40%	60%	100%	0%
n=5	<b>C1q(+)</b> <b>IgG3(+)</b> <b>IgG4(-)</b>	40%	80%	100%	0%
n=3	<b>C1q(+)</b> <b>IgG3(-)</b> <b>IgG4(-)</b>	33%	100%	100%	0%
n=8	<b>C1q(-)</b> <b>IgG3(-)</b> <b>IgG4(+)</b>	25%	63%	88%	13%
n=13	<b>C1q(-)</b> <b>IgG3(+)</b> <b>IgG4(-)</b>	23%	69%	100%	0%
n=75	<b>C1q(-)</b> <b>IgG3(-)</b> <b>IgG4(-)</b>	29%	33%	73%	26%

= functioning graft at end of follow-up   
 = graft loss